Cisplatin - Mesothelioma Chemotherapy Drugs
Cisplatin is a chemotherapy medication that contains platinum. This element is used to treat several forms of asbestos cancer, including mesothelioma. Today, Cisplatin is often combined with newer medications to increase effectiveness of the treatment.
Cisplatin has been on the market for some time, though it was generally found to be ineffective in treating mesothelioma. But when combined with the new chemotherapy drug Alimta, which was approved by the Food and Drug Administration (FDA) in 2005, Cisplatin has proven to be an effective medication. The Alimta and Cisplatin combination is now considered to be one of the most effective chemotherapy treatments for pleural mesothelioma patients that are not candidates for surgery.
Because the drug was introduced approximately 30 years ago and was the first in its class of alkylating agents, it often causes more side effects than newer chemotherapy drugs. Because of this, doctors will often try other chemotherapeutic drugs before recommending treatment with Cisplatin.
Treatment with Cisplatin
Patients prescribed Cisplatin should discuss any potential concerns with their doctor. Make sure to review statistics on the effectiveness of Cisplatin and Alimta, the administration of the drug combination, and the side effects that patients encounter with treatment. It is imperative to take a B12 supplement orally starting a week before treatment begins, as well as weekly B12 shots throughout treatment. Patients should also take folic acid supplements daily (by mouth), which will continue for 21 days after the last dosage cycle of Cisplatin and Alimta. Doctor will also prescribe an oral steroid to help minimize side effects such as skin rash. Patients taking other medications, either prescriptions or non-prescriptions such as supplements, must inform their physician to avoid potential serious drug interactions.
Cisplatin with Alimta is given to mesothelioma patients every 21 days on an outpatient basis, usually at a hospital or cancer treatment center. The treatment consists of a dose of Alimta by IV (which typically lasts about 10 to 15 minutes), followed by Cisplatin (which takes approximately two hours to administer). The number of cycles required will depend on the patient's response to medications, as well as any side effects experienced.
Side Effects of Cisplatin
Side effects of Cisplatin and Alimta are usually mild to moderate for most patients with pleural mesothelioma, and include:
- Nausea
- Vomiting
- Fatigue
- Thinned or brittle hair
- Loss of appetite or weight
- Diarrhea
- Changes in taste
- Numbness or tingling in the fingertips and toes
- Kidney toxicity
- Low white blood cells (neutropenia)
- Low red blood cells (anemia)
Patients experiencing any of the following symptoms should immediately call their doctor:
- Unusual bruising or bleeding
- Black stools
- Fever
- Chills
- Dizziness
- Diarrhea
- Shortness of breath or wheezing
- Swelling of the feet or ankles
- Seizures
- Rash
Some patients may encounter extreme side effects, which should be reported to a medical professional immediately. Cisplatin has the potential of causing serious kidney problems and it is essential to drink plenty of water during treatment with this chemotherapy agent.
Nutrition & Dieting for Cancer
| Learn what foods to eat, which to avoid, and the best supplements for the fight against cancer and chemotherapy recovery. | ![]() ![]() |
Veterans AssistanceAsbestos.com's Veterans Assistance Department can help you with questions about veterans and asbestos-related illnesses or about potential benefits. |
![]() ![]() |
Search through our extensive list of ships that used asbestos-containing products.
(e.g. USS Alabama BB 60)
Mesothelioma BooksTwo must read books for anyone who has or who is caring for someone with mesothelioma. |
![]() ![]() |
Enroll in our Newsletter
Receive a copy of our monthly newsletterwith the latest clinical trials, survivor stories,
doctor profiles, and more.
" Mike Dews, 9-Year Mesothelioma Survivor"
- Mesothelioma Researchers Find Success in Suppressing Growth of Mesothelioma Cells
03/10/2010 - Japanese mesothelioma researchers recently published a study reporting on the success of combining a PLK-1 siRNA with zoledronic acid treatment agains.. - Mesothelioma Cancer will be Recognized During National Asbestos Awareness Week
03/09/2010 - The Asbestos Disease Awareness Organization (ADAO) and other asbestos advocates throughout the United States will be celebrating National Asbestos Awa.. - Mesothelioma Research: Veterans Receive Support with Department of Defense's Increase in Funding
03/08/2010 - The United States Department of Defense has recently announced its intention to increase spending efforts on researching new methods for combating mes..











